Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

YM155, a novel small-molecule that down-regulates survivin, exhibits broad, potent antitumor activity against a range of human tumors. We evaluated the activity of YM155 in aggressive non-Hodgkin lymphoma. In a number of diffuse large B-cell lymphoma lines, YM155 exhibited 50% growth inhibition with values between 0.23 and 3.9 nM. Within in vivo xenograft models, continuous infusion of YM155 eradicated large, established subcutaneous WSU-DLCL-2 and Ramos tumors, with sustained efficacy observed through 4 cycles of YM155 therapy. YM155 increased survival significantly versus rituximab in disseminated Ramos models. This study suggests that YM155 may represent an effective treatment for aggressive lymphomas.

[1]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[3]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[5]  M. Ohira,et al.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma , 2000, Oncogene.

[6]  N. Damle,et al.  Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma , 2004, Clinical Cancer Research.

[7]  田中 慶太朗,et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas , 2000 .

[8]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[9]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Ling,et al.  Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. , 1997, Cancer research.

[11]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[12]  B. Coiffier.  Rituximab therapy in malignant lymphoma , 2007, Oncogene.

[13]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[14]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[15]  S. Ansell,et al.  Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma , 2004, Leukemia.

[16]  A. Tolcher,et al.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Fillet,et al.  [Treatment of non-Hodgkin's lymphoma]. , 1987, Revue medicale de Liege.

[18]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  F. Bosch,et al.  Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. , 2004, The American journal of pathology.

[20]  D. Altieri.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions. , 2006, Current opinion in cell biology.

[21]  M. Fukuoka,et al.  Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines , 2008, Clinical Cancer Research.

[22]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[23]  A. Masamune,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptor Expression and the Pathway of Apoptosis in Human Pancreatic Cancer , 2001, Pancreas.

[24]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[25]  D. Hallahan,et al.  Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma , 2005, Cancer.

[26]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[27]  D. Flavell,et al.  Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used alone , 1995, International journal of cancer.

[28]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Taubert,et al.  Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53 , 2004, Cancer Gene Therapy.

[30]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[31]  S. Fukuda,et al.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. , 2001, Blood.

[32]  G. Rassidakis,et al.  Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Daidone,et al.  Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.